Sign in
4

Changes in Ownership

Edgewise Therapeutics, Inc. Filed Acc 0001562180-22-005384

Options or other derivatives

  • Director acquired 42,087 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
Edris Badreddin Director 2022-06-24 Grant or award · Stock Option (Right to Buy) +42,087 42,087 D
Loading xslF345X03/primarydocument.xml…